|Videos|August 20, 2020

How Anti Science Front Groups Manipulate Legitimate Scientific Debate

Scientists are willing to speak out and have collegial debates – but medical institutions and media have to catch up: fringe voices are often the only ones platformed to discuss important scientific nuances or debates.

"At some point somebody in schools of communication handed down the edict that all science communication must be conducted at the 6th grade level...for years I've had tremendous frustration trying to convey nuance."

Scientists are willing to speak out and have collegial debates — but medical institutions and media have to catch up.

Additionally, some who come forward with genuine credentials aren’t always open about their political motives; fringe voices are often the only ones platformed to advance the important scientific principles of skepticism and debate.

In this clip, we talk to Dr. Peter J. Hotez, Dean for the National School of Tropical Medicine at Baylor College of Medicine. Dr. Hotez discusses the scarcity of good science communication amid the world's first social mediatized pandemic.

Of particular note are the ways political front groups are not up front with their biases, leading to astroturfing that disrupts science conversations about real issues.

Hotez is a physician and researcher with experience in neglected tropical diseases and vaccine development. At Baylor College of Medicine, Hotez is the Dean for the National School of Tropical Medicine. Dr. Hotez is also involved in vaccine development efforts related to SARS-CoV-2.


Related to this article

Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Pfizer 25-Valent Pneumococcal Vaccine Boosts Serotype 3 Response in Infants
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Measles Update: October 23, 2026
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Measles Update: October 16, 2026
The latest CDC numbers show an 8.1% increase in measles cases from week-to-week, bringing the 2026 US total to 4410 confirmed cases. A CDC disease detective is going to Pennsylvania to aid in the state's massive outbreak, and the agency reports on a rare measles complication that is uniformly fatal.